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Adult neurogenesisThe Receptor for Advanced Glycation End-products (RAGE) is a member of the immunoglobulin superfamily
of cell surface receptors which interacts with a wide range of ligands, such as High-Mobility Group Box-1
(HMGB-1), S100B, advanced glycation end-products (AGEs). Here we provided evidence for the restricted
expression of RAGE in the undifferentiated neural stem/progenitor cells of mouse adult SubVentricular Zone
(SVZ) neurogenic region and adult SVZ-derived neurospheres. Additionally, RAGE ligands stimulated both
proliferation and neuronal differentiation of SVZ-derived neural progenitor cells (NPC) in vitro. NF-κB
nuclear translocation occurred upon RAGE activation in SVZ-derived neurospheres and its blockade (by SN-
50) or its absence (in p50−/− derived NPC) resulted in the inhibition of the ligand-mediated effects on
neuronal differentiation. These novel findings delineate an interesting scenario where the RAGE-NF-κB axis
may contribute to regulate adult neural stem/progenitor cell function in physiological and possibly
pathological conditions where this axis is upregulated.vio 6, 28100 Novara, Italy. Fax:
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The Receptor for Advanced Glycation End-products (RAGE) is a
multi-ligand receptor of the immunoglobulin superfamily originally
described as a cell surface receptor for molecules derived from non-
enzymatic glycation and referred to as Advanced Glycation End-
products (AGEs) (Neeper et al., 1992). Since then, additional RAGE
ligands were identified including amyloid β (Aβ)-peptides and fibrils,
constituents of Alzheimer's disease (AD) amyloid plaques, the alarmin
HMGB-1 and the calcium-binding proteins S100/calgranulins (Ding
and Keller, 2005). Furthermore RAGE was identified as a counter-
receptor for the leucocyte β2 integrin Mac-1 (Chavakis et al., 2003).
RAGE exists both as membrane-bound and soluble isoforms (sRAGE),
with the latter ones acting as decoy receptors that bind circulating
ligands (Neeper et al., 1992; Ding and Keller, 2005). Structurally,
membrane-bound full length RAGE (FL-RAGE) consists of three
extracellular immunoglobulin-like domains (one V- and two C-
types), a single transmembrane domain and a short intracellular C-
terminal tail, which is essential for intracellular signalling (Huttunen
et al., 1999; Dattilo et al., 2007). sRAGE isoforms can be generated by
alternative splicing (Hudson et al., 2008; Kalea et al., 2009) or by
proteolytic cleavage of FL-RAGE by ADAM10 (Raucci et al., 2008).
In normal adult tissues, RAGE is usually expressed at low levels,
except in the lung where it is quite abundant (Hudson et al., 2008;Kalea et al., 2009). Upon ligand accumulation in a tissue, RAGE is
commonly upregulated and produces a sustained cell activation
through multiple intracellular signalling pathways (Li and Schmidt,
1997; Bierhaus et al., 2001; Schmidt et al., 2001; Ding and Keller,
2005). A vast array of information has been collected on the possible
contribution of RAGE activation to several diseases such as diabetes,
AD, atherosclerosis, cancer progression and stroke (Schmidt et al.,
2001; Arancio et al., 2004; Ding and Keller, 2005; Fang et al., 2010;
Takuma et al., 2009). For such reasons, RAGE is viewed as an attractive
target for pharmacological intervention in those disorders (Geroldi
et al., 2006; Maczurek et al., 2008).
In the adult central nervous system (CNS), RAGE has been shown
to be expressed at low levels by neurons, glia, endothelial cells and it
has been involved in multiple events including proliferation, neurite
outgrowth, migration and apoptosis (Yan et al., 1996, 1997; Huttunen
et al., 2000; Lue et al., 2001; Chou et al., 2004; Schmidt et al., 2007; Qin
et al., 2008). Among the signalling pathways which lie downstream
RAGE engagement are those involving the NF-κB family of transcrip-
tion factors, whose role in the CNS is widely recognized (Grilli and
Memo, 1999). Additionally, NF-κB p50/p65 dimer has been shown to
activate an autoregulatory positive feedback loopwhereby RAGE itself
is upregulated (Li and Schmidt, 1997; Bierhaus et al., 2001). Recently
our group provided evidence for the selective expression of NF-κB
transcription factors in neurogenic areas of adult mouse brain (Denis-
Donini et al., 2005). Moreover, we demonstrated a selective defect in
adult neurogenesis in NF-κB p50 knock-out mice (Denis-Donini et al.,
2008). Little is known on the possible involvement of RAGE in adult
neurogenesis but, interestingly, Manev et al. (2003) reported that the
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SubGranular Zone (SGZ) after chronic fluoxetine administration, a
treatment known to promote neurogenesis (Santarelli et al., 2003).
Based on these observations, we decided to investigate the potential
role of the RAGE-NF-κB axis in the modulation of adult neurogenesis.
We confirmed that in vivo RAGE is expressed by the neural stem/
progenitor cells in the neurogenic SVZ region of the adult mouse
brain. We also characterized in vitro the expression of the membrane-
bound FL-RAGE isoform in adult mouse neural progenitor cells (NPC).
Moreover, we investigated the functional role of the RAGE-NF-κB axis
in the proliferation and differentiation of adult NPC.
Results
RAGE is expressed in vivo in the SVZ of adult mice
Immunohistochemical analysis using an N-terminal anti-RAGE
antibody confirmed the presence of the receptor in the adult mouse
SVZ region (Fig. 1A–I). To further characterize the RAGE-positive cell
population we performed double-labelling experiments with GFAP
(Glial Fibrillary Acidic Protein), a marker of adult neural stem cells (or
type B cells) and of mature astrocytes, and Sox-2 (anti-SRY-related
HMG-box gene 2), a transcription factor expressed in the nucleus of
undifferentiated stem/progenitor cells (Graham et al., 2003; BrazelFig. 1. RAGE is expressed in vivo in the neural stem/progenitor cells of the adult SVZ reg
immunostained with antibodies against RAGE (A, D and G, green), GFAP (B, red), a marker o
DCX (H, red), a marker of immature neuroblasts. Overlay of the two channels demonstrated
the majority of Sox-2+ cells (indicated by arrowheads) were also immunoreactive f
Magnification=×800. Scale bars=37.5 μm.et al., 2005). As shown in Fig. 1, a subpopulation of GFAP-positive cells
coexpressed RAGE (Fig. 1A–C), while the majority of Sox-2-positive
cells were also immunoreactive for RAGE (Fig. 1D–F). Doublecortin
(DCX) is a microtubule-associated protein expressed by immature
neuroblasts in adult neurogenic areas (Lois and Alvarez-Buylla, 1994).
When RAGE/DCX colabelling was performed, no colocalization was
observed in the adult SVZ (Fig. 1G–I). To further characterize the
nature of the subpopulation of GFAP+/RAGE+ cells in the adult SVZ,
we then decided to performed a triple-labelling experiment with
antibodies against RAGE, GFAP and Sox-2. As shown in Fig. 2A,
virtually all RAGE+/GFAP+ cells were also marked by Sox-2
expression suggesting that they may be identified as undifferentiated
neural stem/progenitor cells (Brazel et al., 2005).
In order to further analyze the expression of RAGE in BrdU+
proliferating cells, a group of adult CD1 mice were administered a
single injection of bromodeoxyuridine (BrdU, 150 mg/kg, intraper-
itoneally) and sacrificed 24 h later. As shown in Fig. 2B, a triple-
labelling experiment with antibodies against RAGE, GFAP and BrdU
demonstrated that BrdU immunoreactivity was absent in the RAGE+/
GFAP+ cells, possibly suggesting that this subpopulation could be
identified as quiescent neural stem cells (type B cells). Conversely,
triple-labelling experiment with antibodies against RAGE, Sox-2 and
BrdU (Fig. 2C) showed that several RAGE+/Sox-2+ cells were marked
by BrdU, possibly suggesting that RAGE is expressed in aion. (A–I) Representative confocal microscopy images of the adult mouse SVZ region
f type B cells or mature astrocytes, Sox-2 (E, red), a marker of stem/progenitor cells, or
that a subpopulation of GFAP+ cells (indicated by arrowheads) coexpressed RAGE (C),
or RAGE (F), while no colocalization was observed between RAGE and DCX (I).
Fig. 2. RAGE is expressed in a subpopulation of quiescent GFAP+/Sox-2+ stem cells and in
proliferating Sox-2+ neural progenitors, but not in migrating neuroblasts. (A–C)
Representative confocal microscopy images of the adult mouse SVZ region. (A)
Immunostaining with antibodies against RAGE (green), GFAP (red) and Sox-2 (blue)
demonstrated that RAGE immunoreactivity is detected in GFAP+/Sox-2+ cells (indicated
by arrowheads) andGFAP−/Sox-2+ cells (indicated by arrows). (B) Immunostainingwith
antibodies against RAGE (green), GFAP (red) and BrdU (blue), showed that the receptor is
expressed in GFAP+/BrdU− cells (indicated by arrowheads) but it is absent in GFAP+/
BrdU+ cells (indicated by arrows). (C) Immunostaining with antibodies against RAGE
(green), Sox-2 (red) and BrdU (blue) demonstrated RAGE expression in a subpopulation
of Sox-2+/BrdU+ cells (indicated by arrowheads). (A–C) Magnification=×800. Scale
bars=37.5 μm. (D) Representative confocal microscopy images of the adult mouse RMS
immunostained with antibodies against RAGE (green), DCX (red) and BrdU (blue)
showed the absence of RAGE immunoreactivity in BrdU+/DCX+ migrating neuroblasts
(indicated by arrowheads). Magnification=×400. Scale bar=75 μm.
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cells. DCX is considered to be a marker of migrating neuroblasts, so we
also performed a triple-staining with antibodies against RAGE, BrdU
and DCX (Fig. 2D) and we analyzed the rostral migratory stream
(RMS), the well-defined route whereby newborn neuroblasts gener-
ated in the SVZ reach their final destination, the olfactory bulb (OB). As
expected, several BrdU+ cells were seen in the RMS, with the majority
of them coexpressing DCX, while RAGE immunoreactivity was totally
absent (Fig. 2D).
By Western blot analysis, the presence of the post-translationally
modified (54 kDa) FL-RAGE protein was confirmed in SVZ protein
extracts by using two distinct commercially available antibodies
which recognize different N- and C-terminal epitopes (Fig. 3A). Lung
extracts were used as positive control.
RAGE is expressed by undifferentiated nestin and Sox-2 positive cells in
SVZ-derived neurospheres
We decided to further investigate the functional significance of
RAGE expression in the SVZ taking advantage of neurosphere cultures,
a widely utilized in vitromodel of adult neural progenitor cells (NPC).
Western blot analysis confirmed the presence of FL-RAGE protein in
SVZ-derived neurosphere extracts by using two antibodies which
recognize different N- and C-terminal epitopes (Fig. 3A). Additionally,
FL-RAGE expression in NPC was confirmed by RT-PCR analysis
(Fig. 3B). Immunocytochemical analysis of non permeabilized SVZ-
derived neurospheres by an antibody which recognizes a N-terminal
extracellular receptor epitope confirmed that RAGE immunoreactivitylocalized at the plasma membrane of neurosphere cells (Fig. 3C–N).
SVZ-derived neurospheres grown in presence of epidermal growth
factor (EGF) and fibroblast growth factor (FGF) are mainly composed
of undifferentiated neural progenitor cells expressingmarkers such as
the intermediate neurofilament nestin (Fig. 3D and G) and Sox-2 (Fig.
3J and M). Double-immunolabelling experiments and confocal z-
plane analysis confirmed that RAGE-positive cells coexpressed nestin
(Fig. 3E and H) and Sox-2 (Fig. 3K and N), suggesting that, in line with
the data reported in vivo, they are undifferentiated neural progenitor
cells.
HMGB-1, S100B and AGE-BSA stimulate neural progenitor cell
proliferation via RAGE activation
During this study, we evaluated the effect of 96 h-exposure to
three different RAGE ligands on NPC proliferation. Concentrations of
HMGB-1 ranging from 1 to 10 ng/ml (40 pM–0.4 nM) significantly
increased proliferation with a maximal effect (20.70%±2.27) at 1 ng/
ml (Fig. 4A; n=15, pb0.001). Similar results were obtained when
cells were treated with S100B. Nanomolar concentrations (0.3–
30 nM) of the ligand significantly increased proliferation (at least
pb0.01) with a maximal effect (20.62%±1.18) elicited at 3 nM
(Fig. 4B; n=12, pb0.001). Finally, increasing concentrations of
Glycated-Bovine Serum Albumin (AGE-BSA), from 25 to 100 μg/ml
(371 nM–1.49 μM), induced proliferation in a dose-dependent man-
ner, with a maximal effect (19.41%±3.55) at 100 μg/ml (Fig. 4C;
n=8, pb0.01). To investigate whether RAGE ligands were involved in
the proliferation of NPC or in their survival, a time-course experiment
was also undertaken. As shown in Fig. 4D, the growth curve in vehicle-
treated NPC suggested a relatively stationary phase up to 48 h
followed by an exponential phase up to 96 h. No difference between
vehicle and ligand-treated cells could be seen up to 48 h. Compared to
vehicle-treated cells, HMGB-1 (1 ng/ml) produced a statistically
significant increase at 72 h (pb0.01) and at 96 h (pb0.001), while
S100B (3 nM) and AGE-BSA (50 μg/ml) only at 96 h (pb0.001 and
pb0.01, respectively). In order to confirm RAGE involvement in the
ligand-mediated effects, cells were treated for 96 h with RAGE ligands
in absence or presence of 20 μg/ml of a neutralizing anti-RAGE
antibody. Effects of 3 ng/ml HMGB-1 (Fig. 4E), 3 nM S100B (Fig. 4F)
and 50 μg/ml AGE-BSA (Fig. 4G) were significantly inhibited by the
neutralizing antibody (n=5, pb0.01 for HMGB-1 and S100B;
pb0.001 for AGE-BSA), confirming that they were indeed receptor-
mediated. Interestingly, when applied alone, the neutralizing anti-
RAGE antibody did not affect neurosphere proliferation (data not
shown).
HMGB-1, S100B and AGE-BSA promote neuronal differentiation of
neural progenitor cells
Upon removal of EGF and FGF from the medium, neural progenitor
cells derived from SVZ neurospheres stop dividing and start to
differentiate. By double immunolabelling for markers of mature
neurons (Microtubule-Associated Protein 2, MAP-2) and glial cells
(GFAP), we could evaluate in vitro the differentiation of NPC toward the
two lineages. After 22 h in absence of growth factors, neurosphere-
derived cells mainly differentiate towards the neuronal lineage, giving
rise to 42.17%±2.45 of MAP-2+ neurons and 5.87%±2.37 of GFAP+
glial cells, over the total number of viable cells (Fig. 5A). Under these
experimental conditions, we evaluated the effect of RAGE ligands on
NPC differentiation. As shown in Fig. 5B, 1 ng/ml HMGB-1 had a
remarkable pro-neurogenic effect, as revealed by double MAP-2/GFAP
immunolocalization. With all RAGE ligands, tested at concentrations
which are active on proliferation, a significant increase in the number of
MAP-2+ neurons was observed in comparison with vehicle-treated
cells (% of MAP-2+ neurons over total viable cells: 42.15%±2.33;
71.94%±3.32; 68.77%±2.79; 70.46%±2.12 for vehicle, 3 nM S100B,
Fig. 3. Expression of FL-RAGE in adult SVZ region and in SVZ-derived neurospheres. (A) Representative immunoblots confirming the presence of the post-translationally modified
form (54 kDa) of FL-RAGE in extracts from undifferentiated SVZ-derived neurospheres (NS), SVZ or lung. Two antibodies recognizing different epitopes (“Ab N-term” and “Ab C-
term”) gave comparable results. (B) RT-PCR analysis of FL-RAGE expression in SVZ-derived neurospheres (NS) and in lung cDNA. A 161 bp PCR product was detected, corresponding
to FL-RAGE isoform. PCR reaction without cDNA (ctrl) served as negative control. The 50 bp DNA ladder was used as molecular weight marker (mwm). (C–N) Representative
fluorescent microscopy images (C–E and I–K) and confocal z-plane analysis (F–H and L–N) of neurospheres immunolabelled with antibodies against RAGE (C, F, I and L, red), nestin
(D and G, green) and Sox-2 (J and M, green). The merged images showed that RAGE immunoreactivity colocalized with nestin (E and H) and Sox-2 (K and N) in SVZ neurosphere
cells. (C–E and I–K) Magnification=×600. Scale bars=56.25 μm. (F–H and L–N) Scale bars=11.5 μm.
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vs vehicle) (Fig. 5C). Conversely, no effect was elicited by RAGE ligands
on the number of newly generated GFAP+ astrocytes, compared to
vehicle-treated cells (Fig. 5D; n=3). Within the time frame of our
experimental conditions no MBP+ oligodendrocytes can be observed
since oligodendrogenesis requires several days in vitro to occur. We
therefore investigated the expression of NG2, a marker of oligoden-
drocyte precursors. We quantified the number of NG2+ positive cells
after 22 h treatment with HMGB-1, S100B, AGE-BSA at concentrations
thatwere active on neuronal differentiation andwe did not observe any
effect compared to vehicle-treated cells (Fig. 5D; n=3).As shown in Fig. 5E, HMGB-1 effects on neuronal differentiation
were receptor-mediated since prevented by pretreating cells with a
neutralizing anti-RAGE antibody (n=3, pb0.001). Similar results
were obtained by antibody pretreatment on AGE-BSA and S100B-
mediated neuronal differentiation (data not shown). When applied
alone, the neutralizing anti-RAGE antibody did not affect NPC
differentiation (Fig. 5E). To investigate whether RAGE activation
could affect the survival of NPC or neuroblasts, we evaluated the
activity of lactate dehydrogenase (LDH) in the differentiationmedium
after 22 h in presence of RAGE ligands or vehicle. As shown in Fig. 5F,
no difference in the LDH activity was observed in themedia of vehicle-
Fig. 4. RAGE activation stimulates the proliferation of adult NPC. (A–C) 96 h treatment with indicated amounts of HMGB-1 (A), S100B (B) and AGE-BSA (C) resulted in statistically
significant increase in NPC proliferation. Data, expressed as % increase over basal (vehicle-treated value), represent the mean±s.e.m. of experiments (n=15 for HMGB-1; n=12 for
S100B; n=8 for AGE-BSA), run in triplicates. *pb0.05; **pb0.01; ***pb0.001 vs vehicle (one-way ANOVA and post-hoc Tukey's test). (D) NPC were treated with 1 ng/ml HMGB-1,
3 nM S100B, 50 μg/ml AGE-BSA or vehicles in a time-course proliferation experiment. Data, expressed as counts per second (CPS), represent the mean±s.e.m. of n=3 experiments,
run in triplicates. **pb0.01; ***pb0.001 vs vehicle (Student's t-test). (E–G) 1 h pretreatment with a neutralizing anti-RAGE antibody (α-RAGE Ab, 20 μg/ml) counteracted the
proliferative effects of 3 ng/ml HMGB-1 (E), 3 nM S100B (F) and 50 μg/ml AGE-BSA (G) on SVZ-derived NPC. Data, expressed as % increase over basal (vehicle-treated), represent the
mean±s.e.m. of n=5 experiments, run in triplicates. **pb0.01; ***pb0.001 (Student's t-test).
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apoptotic nuclei in SVZ derived NPC differentiated in presence of
vehicle or RAGE ligands. As shown in Fig. 5G, no difference was
observed in the percentage of apoptotic nuclei over the total nuclei
number in vehicle- versus RAGE ligand-treated cells.
A functional RAGE-NF-κB axis in adult neural progenitor cells
NF-κB p50/p65 dimer-mediated signalling lies downstream RAGE
activation (Li and Schmidt, 1997; Bierhaus et al., 2001). Therefore we
decided to investigate the presence of a functional RAGE-NF-κB axis in
adult neural progenitor cells. In vivo double RAGE/p65 immunoloca-
lization experiments confirmed that the majority of RAGE-expressingcells of the adult SVZ costained for cytoplasmic NF-κB p65 (Fig. 6A–C).
In vitro, NF-κB p65 immunoreactivity was detected in the cytoplasm of
undifferentiated neurosphere cells (Fig. 6D) and its nuclear transloca-
tion was observed within 30 min after exposure to 10 ng/ml tumor
necrosis factor-α (TNF-α), used as a positive control (Fig. 6E). When
adult SVZ-derived neurospheres were exposed for 30 min to concen-
trations of RAGE ligands active on NPC proliferation and differentiation,
namely 1 ng/ml HMGB-1 (Fig. 6F), 3 nM S100B (Fig. 6G) and 50 μg/ml
AGE-BSA (Fig. 6H), NF-κB p65 nuclear translocation was observed.
These data demonstrated that also in adult SVZ-derived NPC RAGE
activation is coupled to NF-κB signalling. Furthermore, under differen-
tiating conditions, 1 h-pretreatment of NPC with 10 μg/ml SN-50, a
cell-permeable peptide which inhibits NF-κB p50 nuclear translocation
Fig. 5. RAGE activation promotes neuronal differentiation of adult NPC. (A–B) Representative fluorescent microscopy images of MAP-2+ neurons (green) and GFAP+ glial cells (red)
derived from NPC after 22 h treatment with vehicle (A) or 1 ng/ml HMGB-1 (B). Nuclei were stained with Hoechst (blue). Magnification=×1000. Scale bars=33.75 μm. (C) 22 h
treatmentwith indicated concentrations of RAGE ligands significantly increased thepercentageofNPC-derivedMAP-2+neurons compared to vehicle-treatedcells.Data are expressed as%
of MAP-2-positive cells over total viable cells and represent the mean±s.e.m. of n=3 experiments, run in triplicates. ***pb0.001 vs vehicle (Student's t-test). (D) 22 h treatment with
indicated concentrations of RAGE ligands did not significantly change the number of NG-2+ oligodendrocyte precursors (white bars) or GFAP+ glial cells (black bars) compared with
vehicle-treated cells. Data are expressed as % of change over vehicle-treated cells and represent the mean±s.e.m. of n=3 experiments, run in triplicates. (E) 1 h pretreatment with a
neutralizing anti-RAGE antibody (α-RAGE Ab, 20 μg/ml) abolished the effect of 1 ng/ml HMGB-1 on neuronal differentiation of SVZ-derived NPC. When applied alone, the neutralizing
anti-RAGE antibody did not affect neuronal differentiation of NPC. Data are expressed as % of MAP-2-positive cells over total viable cells and represent the mean±s.e.m. of n=3
experiments, run in triplicates. ***pb0.001 vs vehicle (Student's t-test). (F) Evaluation of LDH activities in conditionedmedia of differentiated cell cultures treated for 22 hwith vehicle or
RAGE ligands. No significant difference in LDH activity was observed in the media of vehicle- or RAGE ligands-treated cells. (G) Evaluation of the percentage of apoptotic nuclei in
differentiated cell cultures treatedwith vehicle or RAGE ligands for 22 h. No significant differencewas observed comparing vehicle- or RAGE ligands-treated cells. (F–G)Data represent the
mean±s.e.m. of n=3 experiments, run in triplicates.
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MAP-2+ neurons induced by all RAGE ligands (Fig. 6I–M; n=3,
pb0.001). As a control, cell culture treatmentwith 10 μg/ml of SN-50 M
inactive peptide (Lin et al., 1995) did not counteract RAGE ligand-
mediated effects on NPC neuronal differentiation (Fig. 6M). To confirm
the involvement of NF-κB in the effects of RAGE ligands, we utilized
wild-type (wt) and NF-κB p50−/− derived SVZ neurospheres. Under
basal conditions, no difference in neuronal differentiation of SVZ-
derived NPC was observed between the two genotypes (Fig. 6N; n=3).As expected, in NPC from wt mice RAGE ligands significantly increased
the percentage of MAP-2+ neurons over the total viable cells (Fig. 6N;
n=3, pb0.01 for 1 ng/ml HMGB-1 and pb0.001 for 3 nM S100B and
50 μg/ml AGE-BSA). Conversely, the receptor activation by
RAGE ligands produced no effect on neuronal differentiation of NF-κB
p50−/−-derived SVZ neural progenitor cells (Fig. 6N; n=3).
Overall, these data confirmed the involvement of NF-κB signalling,
and in particular of p50-containing dimers, in the RAGE-mediated
effects on differentiation of adult SVZ-derived neural progenitor cells.
Fig. 6. Functional RAGE-NF-κB axis in adult neural progenitor cells. (A–C) Representative confocal microscopy images of adult mouse SVZ region immunostained with antibodies
against RAGE (A, green) and NF-κB p65 (B, red). Overlay of the two channels (C) confirmed RAGE colocalization in p65-expressing cells (indicated by arrowheads).
Magnification=×800. Scale bars=37.5 μm. (D–H) RAGE ligands induced NF-κB p65 nuclear translocation in undifferentiated SVZ-derived neurospheres. Confocal microscopy
images showing cytoplasmatic (D) or nuclear (E–H) NF-κB p65 mmunostaining. Neurospheres were exposed for 30 min to vehicle (D), 10 ng/ml TNF-α (E), or to 1 ng/ml HMGB-1
(F), 3 nM S100B (G), 50 μg/ml AGE-BSA (H). Magnification=×800. Scale bars=37.5 μm. (I–M) The inhibition of NF-κB nuclear translocation by 1 h pretreatment with SN-50
peptide (10 μg/ml) completely prevented the increase in MAP-2+ neurons induced by 50 μg/ml AGE-BSA (I), 3 nM S100B (L) and 1 ng/ml HMGB-1 (M). When applied alone, SN-50
peptide did not affect the differentiation of NPC (I–M). SN-50 M (negative control peptide) did not counteract HMGB-1-mediated effect on NPC neuronal differentiation (M). (N)
22 h treatment with 1 ng/ml HMGB-1, 3 nM S100B and 50 μg/ml AGE-BSA or vehicle of wt and NF-κB p50−/− SVZ NPC. Compared to vehicle, RAGE ligands significantly increased
the percentage of MAP-2+ neurons from wt but not in p50−/− derived SVZ neural progenitor cells. (I–N) Data are expressed as % of MAP-2-positive cells over total viable cells and
represent the mean±s.e.m. of n=3 experiments, run in triplicates. **pb0.01, ***pb0.001 vs vehicle (Student's t-test).
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RAGE has been extensively investigated for its potential contri-
bution to chronic disorders such as diabetes, atherosclerosis, cancer
and AD, as well as to acute conditions such as cardiac ischemia,
stroke and trauma (Arancio et al., 2004; Rong et al., 2005;
Muhammad et al., 2008; Fang et al., 2010; Hassid et al., 2009;
Riehl et al., 2009; Takuma et al., 2009; Yan et al., 2009). Within the
CNS, RAGE is expressed on neurons, glia, endothelial cells and it was
demonstrated to be involved in multiple biological events including
cell proliferation, neurite outgrowth, migration, apoptosis (Yan
et al., 1996, 1997; Huttunen et al., 1999, 2000; Lue et al., 2001; Chouet al., 2004; Schmidt et al., 2007; Qin et al., 2008). Now we propose a
novel functional role for RAGE in CNS, namely the modulation of
proliferation and neuronal differentiation of adult neural progenitor
cells. Here we provided evidence for the expression of RAGE in the
adult murine SVZ neurogenic region and in adult SVZ-derived
neurospheres. In particular, we demonstrated that in vivo RAGE
immunoreactivity was present in GFAP+/Sox-2+ neural stem cells,
characterized by a low proliferation rate (RAGE+/GFAP+/BrdU−
cells) as reported in quiescent type B cells, and in the majority of
transit amplifying Sox-2+/BrdU+ neural progenitor cells (likely
corresponding to type C cells) of the adult SVZ. In parallel, RAGE was
expressed by nestin+ and Sox-2+ progenitor cells in SVZ derived
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immunoreactivity in newborn DCX+ migrating neuroblasts in SVZ
and RMS. Since RAGE expression was absent in OB of adult mice and
in MAP-2+ mature neurons derived from the differentiation of SVZ
neurospheres (data not shown), altogether these data support the
idea that the receptor expression is restricted to SVZ undifferenti-
ated stem/progenitor cells. Additionally, we demonstrated that
RAGE ligands such as HMGB-1, S100B and AGE-BSA stimulated
proliferation of NPC in vitro. When SVZ-derived NPC were cultured
under differentiating conditions, the activation of the receptor
significantly increased the number of newly generated MAP-2+
neurons, without any relevant effect on GFAP+ astrocytes or NG2+
oligodendrocyte progenitors. Additionally, no significant differences
were observed in the number of apoptotic nuclei and in LDH activity
in conditioned media of NPC cells differentiated in presence of RAGE
ligands or vehicle, suggesting that RAGE activation did not affect
survival of NPC and/or neuroblasts and/or post-mitotic neurons.
Both proliferation and neuronal differentiation properties of RAGE
ligands appeared to be receptor-mediated since they were inhibited
by the pretreatment with a neutralizing anti-RAGE antibody.
Neurogenesis is a process resulting from the complex interplay of
proliferation, differentiation and cell survival/death events. The
available literature data show that in some instances, increased
proliferation of SVZ neural stem/progenitor cells can result in
reduced neuroblast formation (Kuhn et al., 1997; Jackson et al.,
2006). Conversely, several in vivo and in vitro studies demonstrated
that the two events could also proceed in parallel. For example, the
dopamine receptor agonists increased both the proliferation and the
neuronal differentiation of SVZ progenitors both in vitro and in vivo
(O'Keeffe et al., 2009; Winner et al., 2009).
We also provided evidence for the presence of a functional RAGE-
NF-κB axis in adult NPC. NF-κB p65 nuclear translocation occurred
upon RAGE activation in SVZ-derived neurospheres and blockade of
NF-κB p50 translocation by SN-50 peptide resulted in inhibition of
ligand-mediated effects on neuronal differentiation of neural progen-
itor cells. To further confirm NF-κB involvement, RAGE activation
significantly enhanced neuronal differentiation in wt NPC-derived
cells, while p50-deficient NPC were unresponsive. Finally, our in vitro
observations were corroborated by in vivo data demonstrating the
presence of NF-κB p65 immunoreactivity in RAGE-positive stem/
progenitor cells of adult mouse SVZ neurogenic niche.
Our data on a RAGE-NF-κB axis positively modulating SVZ neu-
rogenesis are in line with other results showing that NF-κB signalling is
involved in either differentiation and/or proliferation of NPC. Bernar-
dino et al. (2008) demonstrated that the activation of tumor necrosis
factor receptor 1 (TNFR1),which in turn activates NF-κB, increased both
proliferation and neuronal differentiation of neurospheres derived from
neonatal SVZ. Similar results were obtained by Widera et al. (2006) on
neurospheres derived from adult SVZ. In vivo, Shingo et al. (2001)
demonstrated that erythropoietin positively regulates the neuronal
differentiation in the adult SVZ through a homeostatic autocrine/
paracrine mechanism resulting in NF-κB activation.
Interestingly, available literature data point to more complex
activities of the NF-κB signalling in the adult hippocampal neurogenic
region. As an example, activation of TNFR1 and interleukin 1 (IL-1)
receptors, which are upstream of NF-κB activation, resulted in
inhibition of hippocampal neurogenesis (Iosif et al., 2006; Kaneko
et al., 2006; Goshen et al., 2008). Rolls et al. (2007) demonstrated both
in vitro and in vivo that Toll-like receptors (TLR) 2 and 4 showed
distinct and opposite effects on the adult hippocampal neurogenesis
by triggering MyD88 and Protein Kinase C α/β-dependent activation
of the NF-κB signalling pathway. Our group recently demonstrated a
selective defect in adult hippocampal neurogenesis in NF-κB p50
knock-out mice, possibly occurring at the transition between the
maturation stages of newly born neuroblasts/neurons marked by the
expression of DCX and Calretinin (Denis-Donini et al., 2008).These results are not surprising. The neural stem/progenitor cells
of the two neurogenic areas likely represent distinct cell populations,
endowed with different differentiative potential, which differentially
respond to physiological and pathological stimuli. Interestingly, we
have recently evaluated if any alterationwas present in the SVZ region
of NF-κB p50−/−mice. No defect could be observed in the SVZ and in
the OB of p50−/− compared to wt mice, revealing a hippocampus-
specific influence of this NF-κB family member (Grilli et al., data
unpublished).
Additionally, NF-κB is a family of transcription factors whose
members can differently combine to form hetero- and homo-dimers
of different composition (Grilli et al., 1993). Their regulatory
specificity is dependent on their distinct affinities for cofactors and
κB consensus elements in target genes and therefore they can elicit
multiple, even opposite, functions within the same cell type in the
CNS (Leung et al., 2004; Pizzi and Spano, 2006). In this complex
context, the involvement of NF-κB in the regulation of adult
neurogenesis should also take into account that distinct members of
the family may be involved in fine tuning of adult neurogenesis, with
dimers of different composition playing different and even opposite
role in neural stem/progenitor cells.
The functional significance of the RAGE-NF-κB axis in adult SVZ
deserves further investigation but at this stage hypothesis can be
made. A typical feature of RAGE in the brain is that it is expressed at
relatively low levels in physiological conditions while its expression is
strikingly increased in situations characterized by enhanced cellular
activation or stress, like inflammation and neurodegeneration
associated with several neurological disorders. As an example, RAGE
expression is increased in human and experimental stroke (Ma et al.,
2003; Zhai et al., 2008). Additionally, after acute brain damage, RAGE
ligands such as HMGB-1 and S100B are released by necrotic cells and
inflammatory cells (Rothermundt et al., 2003; Goldstein et al., 2006;
Kim et al., 2006; Mori et al., 2008; Qiu et al., 2008). Cerebral ischemia
is also associated with strong NF-κB activation in neurons, astrocytes,
microglia, and infiltrating inflammatory cells (Ridder and Schwanin-
ger, 2009). In turn, NF-κB activation causes the receptor up-regulation
through a feed forward signal transduction mechanism, since the
presence of NF-κB binding sites in the RAGE promoter region (Li and
Schmidt, 1997). According to the general view, in acute brain damage
activation of the RAGE-NF-κB axis is deleterious (Mori et al., 2008;
Muhammad et al., 2008; Hassid et al., 2009). Recently, Muhammad
et al. (2008) provided evidence that in stroke the HMGB-1-RAGE
signalling links necrosis with apoptosis and suggested that the
receptor may represent a valuable target for anti-inflammatory
therapy in cerebral ischemia. Additionally, a potential contribution
of AGEs to neurotoxicity and brain damage during ischemic stroke has
been suggested (Zimmerman et al., 1995).
The novel finding of a functional RAGE-NF-κB axis in adult neural
progenitor/stem cells adds complexity to the scenario of RAGE
contribution to brain damage. Indeed there is a substantial evidence
supporting enhanced cell proliferation after injury in regions of the
adult brain known to harbour neural stem/progenitor cells, and in
particular in the SVZ region (Jin et al., 2001; Chen et al., 2003;
Romanko et al., 2004; Jin et al., 2006). Additionally, a number of
studies indicate that after ischemic and traumatic brain injury the
cells of adult SVZ not only have the capacity to replenish their own
numbers, but also to replace neurons and glia (Chen et al., 2003).
Moreover, intracerebroventricular (icv) injection of S100B following
traumatic brain injury resulted in strongly increased hippocampal
neurogenesis (Kleindienst et al., 2005). In particular Kleindienst and
colleagues showed that icv administration of S100B significantly
increased both the number of BrdU-positive cells and the percentage
of BrdU+/NeuN+ neurons in the adult hippocampal neurogenic
region. They also quantified effects of icv injection of S100B in the
SVZ and reported a small but statistically not significant increase in
the number of BrdU-positive cells in this region (Kleindienst et al.,
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increase of NPC proliferation and a dramatic increase of neuronal
differentiation in SVZ NPC, suggesting that this latter effect is
predominant. Unfortunately, Kleindienst et al. (2005) did not analyse
neuronal differentiation in this neurogenic area. Despite this,
preliminary data in our laboratory report that the RAGE-NF-κB axis
is also functionally active in adult hippocampal NPC (data not shown),
suggesting that S100B may actually promote neurogenesis in this
area via NF-κB.
Overall, the presence of RAGE in the SVZ region of adult mice may
suggest a potential role of the multiligand receptor in a pro-neurogenic
response to brain injury, possibly via NF-κB-mediated transcription.
This hypothesis is in linewith recent experimental evidence obtainedby
our group that the NF-κB family of transcription factors is involved in
adult neurogenesis (Denis-Donini et al., 2008). Furthermore, the data
presented in this paper suggest the Janus-faced nature of RAGE in
situations of brain damage. Indeed, in the area of inflammation and
neurodegeneration, RAGE axis activation in inflammatory cells such as
macrophages/microglia appears to be detrimental (Muhammad et al.,
2008). Conversely, in the SVZ stem/progenitor cells RAGE axis
activation in response to damage may potentially contribute to
endogenous mechanisms of repair, such as neurogenesis.
RAGE is currently viewed as an attractive target for pharmacolog-
ical intervention in several neurological disorders including acute
brain damage. The mechanisms behind the complex RAGE-mediated
responses would imply the need to search for agents that may inhibit
RAGE detrimental and maladaptive effects without compromising the
potentially adaptive ones like neurogenesis.
Experimental methods
Animals
Adult (4–6 month-old) male CD1 mice, purchased from Charles
River Laboratories, and adult (4–6 month-old) NF-κB p50−/− (B6;
129P2-Nfκb1 tm1 Bal/J) and wild-type (B6; 129PF2) male mice,
obtained from the Jackson Laboratories, were utilized throughout this
study. All animals were maintained in high-efficiency particulate air
(HEPA)-filtered Thoren units (Thoren Caging System) at the Univer-
sity of Piemonte Orientale animal facility and they were kept in
number of 3–4 animals/cage with unlimited access to water and food.
Care and handling of animals were performed in accordance with the
NIH guidelines and also reviewed and approved by the local IACUC.
Isolation and culture of adult SVZ neurospheres
For neurosphere preparation, the brains from three adult male
mice were dissected and the SVZ was isolated under a dissecting
microscope. Detailed procedure was previously described (Denis-
Donini et al., 2008). Primary (Passage 1, P1) neurospheres were
dissociated after 7 days in vitro (D.I.V.), whereas P2-P9 neurospheres
every 5 D.I.V.. At each passage, cells were plated in 25-cm2 Falcon cell-
culture flask (Becton Dickinson Labware) at a density of 12,000 cells/
cm2 in proliferation medium [Neurobasal-A serum-free medium
(Gibco-Invitrogen) containing B27 supplement (Gibco-Invitrogen),
2 mM L-glutamine (Gibco-Invitrogen), 10 ng/ml basic human FGF
(Peprotech), 20 ng/ml human EGF (Sigma-Aldrich), 4 μg/ml heparin
sodium salt (Sigma-Aldrich) and 100 U/100 μg/ml Penicillin/Strep-
tomycin (Gibco-Invitrogen)]. P3-P9 neurospheres were utilized to
study proliferation and differentiation.
Neural progenitor cell proliferation
Dissociated NPC were plated at the density of 10,000 cells/well in
LuminNUNC F96 MicroWell (NUNC) in proliferation medium in
presence of increasing concentrations of RAGE ligands [0.3–30 nMS100B protein from bovine brain (Calbiochem), 0.3–10 ng/ml human
recombinant HMGB-1 (Sigma-Aldrich) and 25–100 μg/ml AGE-BSA
(Sigma-Aldrich)] or vehicle (Tris–HCl 50 mM pH 7.8) for 96 h. For
neutralization assays, NPC were pretreated for 60 min with 20 μg/ml
neutralizing polyclonal anti-RAGE antibody (R&D systems) before
RAGE ligand or vehicle addition. The proliferation rate was deter-
mined by using the CellTiter-Glo Luminescent Cell Viability Assay
(Promega), according to manufacturer instructions. All experiments
were run in triplicates by using different cell preparations and
repeated at least five times. Data are expressed as percent increase
over basal conditions (vehicle-treated cells) or as counts per second
(CPS) and represent the mean value±s.e.m. To assess NF-κB p65
nuclear translocation, neurospheres were plated at the density of
1000 neurospheres/ml in 24-well plates in proliferation medium and
treated for 30 min with vehicle (Tris–HCl 50 mM pH 7.8), 10 ng/ml
TNF-α (Peprotech), 1 ng/ml HMGB-1, 3 nM S100B, 50 μg/ml AGE-
BSA. Thereafter, neurospheres were harvested on super-frost micro-
scope slides (Menzel-Glaser) by cytospin centrifugation (235×g,
5 min) and fixed with ice-cold 4% paraformaldehyde (PFA) in PBS for
20 min at RT for subsequent immunofluorescent analysis. This
analysis was repeated three times by using neurospheres at different
passages derived from different cell preparations.
Neural progenitor cell differentiation
For differentiation, P3-P9 neurospheres were dissociated and
plated onto laminin-coated (2.5 μg/cm2) Lab-Tek 8-well permanox
chamber slides (NUNC) at a density of 43,750 cells/cm2 in differen-
tiating medium [Neurobasal-A medium containing B27 supplement,
2 mM L-glutamine and 100 U/100 μg/ml Penicillin/Streptomycin].
Under these experimental conditions, NPC differentiate predomi-
nantly into neurons. NPC were treated in presence of indicated
concentrations of S100B, HMGB-1 and AGE-BSA or vehicle (Tris–HCl
50 mM, pH 7.8) for 22 h. For neutralization, NPC were pretreated for
60 min with 20 μg/ml neutralizing polyclonal anti-RAGE antibody
before RAGE ligand or vehicle addition. For NF-κB p50 inhibition,
10 μg/ml NF-κB SN-50 peptide (Calbiochem) or 10 μg/ml NF-κB SN-
50 M peptide (Calbiochem) were added to NPC 60 min before RAGE
ligand or vehicle addition. Then cells were washed in PBS and fixed
with ice-cold 4% PFA for 20 min at RT for subsequent immunofluo-
rescent analysis. In each experiment, 10 fields/well were counted by
using a fluorescent microscope ECLIPSE E600 (NIKON) with a X60
objective. All experiments were run in triplicates by using different
cell preparations and repeated at least three times.
Assessment of cell viability
Dissociated NPC were differentiated, as previously described, in
presence of indicated concentrations of S100B, HMGB-1 and AGE-BSA
or vehicle (Tris–HCl 50 mM, pH 7.8) for 22 h. Media of each samples
were collected and LDH activity in the culture supernatants was
evaluated by using Cytotoxicity Detection Kit LDH (Roche Applied
Science), according to manufacturer instructions. Data are expressed
as values of absorbance (490 nm) of the red formazan salt generated
in a two-step reaction catalyzed by LDH enzyme. In parallel, in order
to evaluate the percentage of apoptotic cells, nuclei of RAGE ligand- or
vehicle-treated cells were counterstained with 0.8 ng/ml Hoechst
(Sigma-Aldrich) diluted in PBS. The number of apoptotic nuclei was
counted in each samples using a fluorescent microscope ECLIPSE E600
(X600). All experiments were run in triplicates by using different cell
preparations and repeated at least three times.
Immunocytochemistry
After fixation, neurospheres or differentiated cells were washed
three times in PBS and permeabilized in PBS containing 0.48% (vol/
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RAGE immunostaining. The primary antibodies against MAP-2 (1:600,
rabbit monoclonal; Chemicon), GFAP (1:600, mouse monoclonal;
Chemicon), RAGE (1:600, goat polyclonal; Chemicon) and Sox-2
(1:500, rabbit polyclonal; Chemicon) were incubated for 150 min at
RT, whereas the primary antibodies against Nestin (1:4000, chicken
polyclonal; Neuromics) and p65 (1:500, rabbit polyclonal; Santa Cruz
Biotechnology) were incubated overnight at 4 °C in an antibody
solution containing 16% (vol/vol) donkey or goat serum (Sigma-
Aldrich). Secondary antibodies were as follows: Alexa Fluor 594-
conjugated donkey anti-goat (1:1200; Molecular Probes), Alexa Fluor
555-conjugated donkey anti-goat (1:1200; Molecular Probes), Alexa
Fluor 488-conjugated donkey anti-rabbit (1:1600; Molecular Probes),
Alexa Fluor 594-conjugated donkey anti-mouse (1:1400; Molecular
Probes) and Alexa Fluor 488-conjugated goat anti-chicken (1:1400;
Molecular Probes). Nuclei were counterstained with 0.8 ng/ml
Hoechst diluted in PBS. Slides were coverslipped with Fluorescent
Mounting Medium (DakoCytomation) as anti-fading agent. Incuba-
tion without primary antibodies served as negative control for
immunocytochemistry. Fluorescent microscope or laser scanning
confocal microscope (Leica TCS-NT) was used for analysis. Adobe
Photoshop CS (Adobe Systems, Inc) was used for digital processing of
the images. Only light intensity, brightness, and contrast adjustments
were applied to improve information.
RNA isolation and Reverse Transcriptase-PCR analysis
Total mRNA was extracted from SVZ-derived NPC (0.5–1.5×106
cells) and lung tissue of adult mice by using the SV Total RNA Isolation
System (Promega), according to manufacturer instructions. The cDNA
was obtained by using the ImProm-II Reverse Transcription System kit
(Promega). The primer sequences used for PCR amplification were as
follows: FL-RAGE, sense 5′-CGATGAGGGGCCAGCTGAAG-3′ (exon 9)
and antisense 5′-CCTGGCTTTCCGGGGCCTTC-3′ (exon 11). PCR reac-
tions were carried out by using GoTaq Flexi DNA polymerase
(Promega) in a final volume of 25 μl containing 56 ng cDNA, 0.4 mM
of each primers, 0.2 mM dNTPs, 2.5 mM MgCl2. PCR conditions were:
94 °C for 10 min; 40 cycles, 94 °C for 30 s, 67.6 °C for 30 s, 72 °C for
1 min; final elongation at 72 °C for 10 min. PCR products were run
onto 2% agarose gels and bands visualized by staining with ethidium
bromide (Sigma-Aldrich).
Protein isolation and Western blot analysis
For protein isolation, tissues from adult mice and SVZ-derived
neurospheres were disrupted in hypotonic RIPA buffer [50 mM Tris–
HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA pH 8, 1% (vol/vol) Triton X-
100, 0.1% (wt/vol) SDS, 1 mM PMSF, 25 mM NaF, 1 mM NaVO4, 1 mM
DTT, protease inhibitor mix (Sigma-Aldrich)]. Neurosphere homoge-
nates were incubated on ice for 25 min. To complete the lysis,
incubation at −80 °C for 3 min followed by 2 min at 37 °C was
repeated three times. Lysates were centrifuged at 15,700 g for 10 min at
4 °C and supernatants were collected. For protein isolation from tissues,
SVZ and lung were disrupted in hypotonic RIPA buffer by using a tissue
homogenizer. Tissue homogenates were incubated on ice for 60 min,
centrifuged at 15,700×g for 30 min at 4 °C and the supernatants were
recovered. Protein concentration was determined by Bradford assay
(Sigma-Aldrich) and equivalent amounts (50 μg) of each sample were
separated onto a 10% (wt/vol) Sodium Dodecyl Sulphate (SDS)-PAGE
gel and transferred onto nitrocellulose membranes. The membranes
were blocked with 5% (wt/vol) BSA in TBS buffer overnight at 4 °C.
Immunoblotswere carried out for 150 min at RT in an antibody solution
containing 3% (wt/vol) BSA in TBS with the following antibodies: anti-
RAGE (1:400, goat polyclonal; AB5484, Chemicon; immunogen:
synthetic peptide corresponding to aa 42–59 of RAGE; marked as “N-
term”) and anti-RAGE (1:1200, rabbit polyclonal; R5278, Sigma;immunogen: synthetic peptide corresponding to aa 362-380 of RAGE;
marked as “C-term”). After washing, blots were incubated with
peroxidase-conjugated goat anti-rabbit (1:10,000; BIO-RAD) or donkey
anti-goat (1:10,000; Santa Cruz Biotechnology) antibodies for 60 min at
RT and the immunocomplexes were visualised by the SupersignalWest
Pico Chemiluminescent substrate (Pierce).
Bromodeoxyuridine treatment and immunohistochemistry
Adult male CD1 mice were administered a single injection of
bromodeoxyuridine (BrdU; 150 mg/kg body weight, intraperitone-
ally) and, 24 h later, they were deeply anaesthetized with Avertin
(400 mg/kg i.p.) and perfused transcardially with saline, followed by
4% ice-cold PFA in 0.1 M phosphate buffer (PB) pH 7.4. Tissues were
prepared as previously described (Denis-Donini et al., 2008). Sections
were incubated with primary antibodies anti-p65 (1:300, rabbit
polyclonal; Santa Cruz Biotechnology), anti-RAGE (1:600, goat
polyclonal; R&D system), anti-GFAP (1:300, mouse monoclonal;
Millipore), anti-DCX (1:200, rabbit polyclonal; AbCAM), anti-Sox-2
(1:800, rabbit polyclonal; Chemicon) and anti-BrdU (1:200, rat
monoclonal, Novus Biological), overnight at 4 °C. For RAGE immuno-
labelling, antigen unmasking with Citrate/EDTA, pH 6.2 at 98 °C for
20 min was performed. The next day, after several washes, sections
were incubated with Alexa Fluor 555-conjugated goat anti-rabbit
secondary antibody (1:300; Molecular Probes), Alexa Fluor 555-
conjugated goat anti-mouse secondary antibody (1:300; Molecular
Probes), Alexa Fluor 555-conjugated donkey anti-rabbit secondary
antibody (1:300; Molecular Probes), Alexa Fluor 633-conjugated goat
anti-rabbit secondary antibody (1:300; Molecular Probes), Cy5-
conjugated goat anti-rat (1:600; Jackson ImmunoResearch) and
biotinylated horse anti-goat secondary antibody (1:400; Vector
Laboratory) followed by incubation with Fluorescein Streptavidin
(1:100; Vector Laboratory). The sections were then mounted onto
slides and coverslipped with Fluorescent Mounting Medium (Dako-
Cytomation) as anti-fading agent. Incubation of tissue without
primary antibodies served as negative control for immunohistochem-
istry. Fluorescent signals were detected using a confocal scanning
laser microscope with a X20 objective and X40 PL APO oil objective
(1.25 NA), by using an argon laser (exciting at 488 nm) or a helium-
neon laser (exciting at 543–633 nm). Adobe Photoshop CS (Adobe
Systems, Inc.) was used for digital processing of the images. Only light
intensity, brightness, and contrast adjustments were applied to
improve information.
Statistical analysis
In all experiments, data are reported as mean±s.e.m, with at least
three replicates per group. Data were analyzed by Student's t-test or
by one-way ANOVA followed by Tukey's post hoc test. Statistical
significance level was set for p values less than 0.05.
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